GlassScriptPhysician profile
April A Wallace
NPI 1427564079
$2,229.30
in general payments reported to CMS, 2019-2025
19 companies · $546 in 2025
The $546 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $465 · 2023: $708 · 2024: $85.07 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923 · Education: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.20 |
| Education | $415.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $562.31 | 2021-2024 | Evenity, Prolia, Nplate |
| Seagen INC. | $327.19 | 2021-2023 | Tukysa |
| Lilly USA, LLC | $320.01 | 2025 | |
| Janssen Biotech, INC. | $190.55 | 2021-2023 | Tecvayli, Darzalex |
| Novocure INC. | $166.63 | 2023-2024 | Optune |
| Beigene USA, INC. | $124.99 | 2022 | |
| Daiichi Sankyo INC. | $107.28 | 2023-2025 | Injectafer, Datroway |
| Epizyme, INC. | $72.64 | 2021 | |
| Abbvie INC. | $60.02 | 2023 | |
| Celgene Corporation | $53.13 | 2025 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $43.39 | 2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $42.41 | 2025 | |
| Caris Mpi, INC. | $41.93 | 2025 | Mi Cancer Seek |
| Astrazeneca Pharmaceuticals LP | $27.01 | 2022 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Lynparza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.80 | 2022 | |
| Genzyme Corporation | $18.73 | 2023 | |
| Intuitive Surgical, INC. | $13.53 | 2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.